Rosiglitazone and cardiotoxicity--weighing the evidence.

  title={Rosiglitazone and cardiotoxicity--weighing the evidence.},
  author={David Matthew Nathan},
  journal={The New England journal of medicine},
  volume={357 1},
The recently published meta-analysis by Nissen and Wolski,1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar magnitude, albeit nonsignificant, in the risk of death from cardiovascular causes, has created a furor in the press and a quandary for physicians and their patients. Given the vagaries of meta-analyses in general and of this meta-analysis in particular — owing to the absence of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 56 extracted citations


Publications referenced by this paper.
Showing 1-8 of 8 references

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes ( RECORD ) Study : interim findings on cardovascular hospitalizations and deaths

  • PD Home, SJ Pocock, H Beck-Nielsen
  • N Engl J Med
  • 2007

Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes ( UKPDS 34 )

  • PD Home, SJ Pocock, H Beck-Nielsen
  • Diabetologia
  • 2005

Similar Papers

Loading similar papers…